Leena Gandhi

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. ncbi Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors
    Leena Gandhi
    Dana Farber Cancer Institute, Boston, MA, USA
    J Clin Oncol 29:909-16. 2011

Detail Information

Publications1

  1. ncbi Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors
    Leena Gandhi
    Dana Farber Cancer Institute, Boston, MA, USA
    J Clin Oncol 29:909-16. 2011
    ..A phase I study of navitoclax, a novel inhibitor of Bcl-2 family proteins, was conducted to evaluate safety, pharmacokinetics, and preliminary efficacy in patients with solid tumors...